<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "aldesleukin inj VIAL">
<dose><value>600 000</value>
<value>600 000 - 720 000</value>
<value>18 000 000</value>
<value>9 000 000</value>
</dose><route><value>IV</value>
<value>SC</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>aldesleukin inj VIAL</value>
</drugname><strength><value>22 million unit</value>
</strength><frequency><value>Q8H</value>
<value>DAILY</value>
</frequency><instruction><value>Administer over 15 minutes for 14 doses.</value>
<value>for 5 days, then rest 2 days.</value>
<value>for 2 days.</value>
<value>for 3 days.</value>
</instruction><volume></volume><units><value>unit/kg/dose</value>
<value>unit </value>
<value>unit</value>
</units><additionalnotes><value>Malignant Melanoma. Treatment schedule = 14 doses, rest 9 days.</value>
<value>Renal Cell Carcinoma.  Treatment schedule = 14 doses, followed by 9 days of rest.</value>
<value>Renal Cell Carcinoma. Treatment schedule: 18 million units SC DAILY for 5 days, rest 2 days, then 9 million units SC DAILY for 2 days, then 18 million units SC DAILY for 3 days.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3334</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>2130181</value>
</din></drug>